{"nctId":"NCT00605267","briefTitle":"Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment","startDateStruct":{"date":"2007-10"},"conditions":["Breast Cancer"],"count":197,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tamoxifen","Drug: Goserelin acetate (Zoladex)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Anastrazole (Arimidex)","Drug: Goserelin acetate (Zoladex)"]}],"interventions":[{"name":"Tamoxifen","otherNames":["NOLVADEX"]},{"name":"Anastrazole (Arimidex)","otherNames":["ARIMIDEX","ZD1033"]},{"name":"Goserelin acetate (Zoladex)","otherNames":["ZOLADEX"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Premenopausal, estrogen receptor positive women, aged 20 years and over, with operable and measurable breast cancer who have provided written informed consent\n\nExclusion Criteria:\n\n* Medical history of chemotherapy or endocrine therapy for breast cancer, or with treatment history of radiotherapy. Unwillingness to stop taking any drug known to affect sex hormone status (including hormone replacement therapy (HRT).","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Best Overall Response Rate (BORR) (Calliper)","description":"The BORR were defined as the percentage of patients with confirmed CR or PR in the ITT population during 24 weeks pre-operative treatment period (based on the data from calliper measurement).\n\nCR (or PR) criteria are met at 2 or more time in points every 4 weeks. Per RECIST Criteria (V1.0) and assessed by Calliper: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.4","spread":null},{"groupId":"OG001","value":"50.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Best Overall Response Rate (BORR) (US)","description":"The BORR were defined as the percentage of patients with confirmed CR or PR in the ITT population during 24 weeks pre-operative treatment period (based on the data from ultra sound (US) measurement).\n\nCR (or PR) criteria are met at 2 or more time in points every 4 weeks. Per RECIST Criteria (V1.0) and assessed by US: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","spread":null},{"groupId":"OG001","value":"42.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Best Overall Response Rate (BORR) (MRI/CT)","description":"The BORR were defined as the percentage of patients with confirmed CR or PR in the ITT population during 24 weeks pre-operative treatment period(based on the data from magnetic resonance imaging (MRI) or computed tomography (CT) measurement).\n\nCR (or PR) criteria are met at either 12 weeks or 24 weeks. Per RECIST Criteria (V1.0) and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>= 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","spread":null},{"groupId":"OG001","value":"37.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Bone Mineral Density (BMD) Lumbar Spine","description":"Change from baseline in Bone Mineral Density value (percentage), in all subjects who used DXA(Dual-energy X-ray absorptiometry) method throughout the study, at 24 weeks measured at lumbar spine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"3.4"},{"groupId":"OG001","value":"-2.9","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Bone Mineral Density (BMD) Cervical Thighbone","description":"Change from baseline in Bone Mineral Density value (percentage), in all subjects who used DXA(Dual-energy X-ray absorptiometry) method throughout the study, at 24 weeks measured at cervical thighbone.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"5.1"},{"groupId":"OG001","value":"-0.5","spread":"3.2"}]}]}]},{"type":"SECONDARY","title":"Bone Turnover Marker (BAP) EIA Method","description":"Change from baseline in serum Bone-Alkaline Phosphatase (BAP) at 24 weeks measured by EIA method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1941","spread":"6.1600"},{"groupId":"OG001","value":"0.7333","spread":"3.3640"}]}]}]},{"type":"SECONDARY","title":"Bone Turnover Marker (BAP) CLEIA Method","description":"Change from baseline in serum Bone-Alkaline Phosphatase (BAP) at 24 weeks measured by CLEIA method","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.96","spread":"4.60"},{"groupId":"OG001","value":"-0.75","spread":"3.10"}]}]}]},{"type":"SECONDARY","title":"Bone Turnover Marker (NTX)","description":"Change from baseline in serum crosslinked N-Telopeptide of type I collagen (NTX) at 24 weeks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.17","spread":"4.74"},{"groupId":"OG001","value":"2.59","spread":"3.23"}]}]}]},{"type":"SECONDARY","title":"Serum Oestrone (E1) Concentrations","description":"Ratio of serum Oestrone (E1) concentration (pg/mL) in the ITT population from baseline at 24 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.028","spread":"0.036"},{"groupId":"OG001","value":"0.341","spread":"0.282"}]}]}]},{"type":"SECONDARY","title":"Serum Oestradiol (E2) Concentrations","description":"Ratio of serum Oestradiol (E2) concentration (pg/mL) in the ITT population from baseline at 24 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.041","spread":"0.092"},{"groupId":"OG001","value":"0.082","spread":"0.186"}]}]}]},{"type":"SECONDARY","title":"Oestrogen Receptor (ER) Status","description":"ER status in the ITT population is categorized as Positive or Negative","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Progesterone Receptor (PgR) Status","description":"PgR status in the ITT population is categorized as Positive or Negative.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Human Epidermal Growth Factor Receptor 2 (HER2) Status","description":"HER2 status in the ITT population is categorized as Positive or Negative","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Histopathological Response Rate (HRR)","description":"Number of patients in the ITT population defined as histopathological responders over the total number of patients x 100. An histopathological responder = a patient classified as Grade 1b, 2 or 3 for the histopathological response (Grade 0 = no response, 1a = mild response, 1b = moderate response, 2 = marked response or 3 = complete response)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.8","spread":null},{"groupId":"OG001","value":"27.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Functional Assessment of Cancer Therapy-Breast (FACT-B)","description":"Change from baseline in Functional Assessment of Cancer Therapy-Breast (FACT-B)in the ITT population at 24 weeks. Trial Outcome Index (TOI) = the sum of the Physical Well-Being (PWB), Functional Well-Being (FWB), and Breast Cancer Scale (BCS) subscales of FACT-B.\n\nFACT-B includes 36 questions; 7 in PWB (Physical Well-Being); 7 inSWB (Social / Family Well-Being); 6 in EWB (Emotional Well-Being); 7 in FWB (Functional Well-Being); 9 in BCS (Breast Cancer Subscale).\n\nTotal score of subscores or TOI is calculated from each score of question. Higher score means better and lower score means worthier.\n\nScore range; 0-28 in PWB; 0-28 in SWB; 0-24 in EWB; 0-28 in FWB; 0-36 in BCS; 0-92 in TOI.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.42","spread":"11.07"},{"groupId":"OG001","value":"-2.65","spread":"8.09"}]}]}]},{"type":"SECONDARY","title":"Endocrine Subscale (ES)","description":"Change from baseline in Endocrine Symptom Subscale (ES)) in the ITT population at 24 weeks. ES score = the sum of the responses to all the questions on ES, low scores reflect poor quality of life and high scores reflects better quality of life.\n\nScore range: 0-72","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.85","spread":"8.69"},{"groupId":"OG001","value":"-6.27","spread":"8.93"}]}]}]},{"type":"SECONDARY","title":"Anastrozole Plasma Concentrations (Cmin)","description":"Trough Plasma concentrations (Cmin) of Anastrozole - only Anastrozole arm was evaluated for Trough Plasma concentrations.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":98},"commonTop":["Hot Flush","Arthralgia","Nasopharyngitis","Headache","Musculoskeletal Stiffness"]}}}